Press Release


For Immediate Release Contact

 

Sue Ducat
Director of Communications
(301) 841-9962
sducat@projecthope.org

   

From Health Affairs:

 

Improved Pneumococcal Vaccine Costs More, But 10-Year Savings Projected

 

 

Bethesda, MD -- In 2010 the US Advisory Committee on Immunization Practices (ACIP) recommended that the pneumococcal seven-valent conjugate vaccine (PCV7) given routinely to children up to two years old be replaced by the pneumococcal thirteen-valent version (PCV13) because of the additional health benefits. Since the new vaccine is more expensive, payers have voiced concerns that these costs could increase health insurance premiums and strain fixed public health agency budgets. A new study, being released as a Web First by Health Affairs, estimated the additional cost of PCV13 use by public and private US insurance payers to be $3.5 billion and $2.6 billion, respectively, over PCV7, between 2010 and 2019. The authors also found that PCV13 could provide net cost savings of $6.14 billion and $4.24 billion, respectively, to those payers by preventing pneumococcal disease and its associated costs, with another $1.66 billion in savings to be realized for uninsured patients.


Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings of $12 Billion

 

By Michele A. Kohli, Raymond A. Farkouh, Michael J. Maschio, Lisa J. McGarry, David R. Strutton, and Milton C. Weinstein

 

http://content.healthaffairs.org/lookup/doi/10.1377/hlthaff.2014.1274

 

Kohli and Maschio are affiliated with Optum in Burlington, Ontario; Farkouh is with Pfizer Vaccines in Collegeville, Pennsylvania; McGarry is affiliated with Ariad Pharmaceuticals, Inc., in Cambridge, Massachusetts; Strutton is with Merck in North Wales, Pennsylvania; and Weinstein is affiliated with the Harvard T.H. Chan School of Public Health, in Boston.

 

This study, also to appear in the July issue of Health Affairs, was supported by Pfizer, Inc.

 

For their study model, the authors combined data from clinical trials, the National Immunization Survey, the Centers for Disease Control and Prevention (CDC), and other sources to estimate the cost of the PCV13 vaccine and the savings associated with preventing pneumococcal disease from 2010-19 in 2013 dollars. "This analysis demonstrates that PCV13 is cost saving for both the public and private sectors," concluded the authors. "Nonetheless, budgetary silos within the sectors may create barriers to adequate funding for implementation of the vaccine. As a result, policy makers will face ongoing challenges as they seek to ensure that all Americans have access to effective and efficient protection from infectious diseases."

 
About Health Affairs
 

Health Affairs is the leading journal at the intersection of health, health care, and policy. Published by Project HOPE, the peer-reviewed journal appears each month in print, with additional Web First papers published periodically at www.healthaffairs.org. The full text of each Health Affairs Web First paper is available free of charge to all website visitors for a one-week period following posting, after which it switches to pay-per-view for nonsubscribers. Web First papers are supported in part by a grant from The Commonwealth Fund. You can also find the journal on Facebook and Twitter. Read daily perspectives on Health Affairs Blog. Download our podcasts, including monthly Narrative Matters essays, on iTunes. Tap into Health Affairs content with the new iPad app.